CClinicalTrials.gg
WithdrawnNCT03224715Updated Jan 12, 2018

Actinic Cheilitis Pre-Treated With DNA Repair Enzyme Cream

An interventional study of DNA Repair Enzyme Cream in Actinic Cheilitis, sponsored by Loyola University. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-12.

Sponsored by Loyola University · Not applicable, Interventional, and Supportive care

Why this study was withdrawn
Project was withdrawn and never began at Loyola University Medical Center.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

It is well known that ultraviolet (UV) light causes sunburn and DNA damage that can lead to skin cancer. Despite preventative measures of sunscreens and other topicals the incidence of skin cancers continues to increase every year. Chronic exposure can lead to development of both basal and squamous cell carcinoma that also is correlated to the risk of melanoma. When epidermal keratinocytes are exposed to UV radiation, they form cyclobutane pyrimidine dimmers (CPDs), 6-pyrimidine-4-pyrimidones (6-4-PPs), and oxygen radicals that alter the structure of nucleotides. When these lesions are not repaired, DNA replication is altered that leads to mutations in p53 and PTCH tumor suppressor gene and ultimately tumor development. It has been discovered that intracellular delivery of bacterial DNA incision repair enzyme T4 endonuclease V DNA repair enzymes can repair sun induced damaged DNA in patients with xeroderma pigmentosum4,. Yarosh et al also showed that T4 endonuclease V DNA repair enzymes are specific to reducing the amount of cyclobutane pyrimidine dimers and were found to lower the rate of new actinic keratoses compared to placebo lotion by 68% with no adverse effects observed. Additionally Yarosh et al also showed that T4N5 liposomes can repair keratinocyte DNA in skin cancer patients. This study will examine if pretreating actinic cheilitis with DNA repair enzyme cream before standard treatments can decrease the need for additional and possibly more aggressive therapies, decrease the surface area of affected areas, and possibly improve skin thickening and texture.

02

Conditions studied

  • Actinic Cheilitis
03

In context

Lead sponsor

Loyola University is the lead sponsor of 132 studies on the registry; 15 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 23 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 years or older with clinically confirmed actinic cheilitis
  • Fitzpatrick Type I, II, III, or IV skin.
  • At least 20% of upper and/or lower lip affected by actinic cheilitis

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing
  • Allergies to any component of the study topical medication
  • Prior treatment of actinic cheilitis within the past month, including cryotherapy, PDT, 5-FU, Picato, Retinoid, Diclofenac
  • Prior ablative laser therapy to the lips, including fractional erbium and CO2 lasers.
  • Prior use of lip fillers
  • Presence of any skin disease that might interfere with the study treatments, including, but not limited to, rosacea, atopic dermatitis, lip lickers dermatitis, perioral dermatitis, perleche, active herpes infection.
  • Presence of hypertrophic and hyperkeratotic lesions or cutaneous horns within the treatment area
  • Any diagnosis of active, untreated skin cancer of the lip
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Actinic Cheilitis patients

    Other: DNA Repair Enzyme Cream

Interventions

  • OtherDNA Repair Enzyme Cream

    ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done

06

What researchers measure

Primary outcomes

  1. Rate of complete clearance vs partial response, determined clinically and by high-resolution macrophotography through blinded dermatologist evaluation

    Percentage of patients with no clinically visible remaining lesions in treated area For partial responders: differentiate approximate surface area of affected lips, expressed as a percentage (0 to 100), compared with that prior to treatment

    Time frame: 12 weeks

07

Study locations

1 site
  • Loyola Dermatology
    La Grange Park, Illinois 60526, United States
08

References and documents

Publications

  • de Berker D, McGregor JM, Hughes BR; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007 Feb;156(2):222-30. doi: 10.1111/j.1365-2133.2006.07692.x. Erratum In: Br J Dermatol. 2008 Apr;158(4):873. PubMed 17223860 ↗
  • Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet. 2001 Mar 24;357(9260):926-9. doi: 10.1016/s0140-6736(00)04214-8. PubMed 11289350 ↗
  • Mouret S, Baudouin C, Charveron M, Favier A, Cadet J, Douki T. Cyclobutane pyrimidine dimers are predominant DNA lesions in whole human skin exposed to UVA radiation. Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13765-70. doi: 10.1073/pnas.0604213103. Epub 2006 Sep 5. PubMed 16954188 ↗
  • Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. 1968. DNA Repair (Amst). 2004 Feb 3;3(2):183-87. PubMed 15344228 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03224715
Lead sponsor
Loyola University
Responsible party
Rebecca Tung (Director of Dermatology, Loyola University) — Principal investigator
First posted
Jul 21, 2017
Start date
Sep 1, 2017 (estimated)
Primary completion
Dec 1, 2017 (estimated)
Completion
Jan 31, 2018 (estimated)
Last update
Jan 12, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion